However, obesity does not appear to influence the expression status of PTPRD in GBM patients, and the levels of expression amongst these patients are not of a clinical utility as a prognostic biomarker. This evidence concerns the gene PTPRD and obesity due to melanocortin 4 receptor deficiency.